Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease
1. Patients who received AK002, lirentelimab, had far greater reductions in both gastrointestinal eosinophil burden and gastrointestinal symptoms compared to ...
1. Patients who received AK002, lirentelimab, had far greater reductions in both gastrointestinal eosinophil burden and gastrointestinal symptoms compared to ...
1. Evinacumab significantly lowered low-density lipoprotein (LDL) cholesterol levels in patients with homozygous familial hypercholesterolemia. 2. Patients receiving evinacumab did ...
1. Prophylactic nirsevimab lowered the incidence of respiratory syncytial virus (RSV)-associated lower respiratory tract infection compared to the placebo group. ...
1. Approximately a quarter of multiple myeloma patients that had refractory disease despite treatment with a proteasome inhibitor, immunomodulatory agent, ...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.